Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis.

Kuusalo L, Puolakka K, Kautiainen H, Karjalainen A, Malmi T, Paimela L, Leirisalo-Repo M, Rantalaiho V; NEO-RACo Study Group.

Clin Rheumatol. 2018 Jun;37(6):1689-1694. doi: 10.1007/s10067-017-3958-1. Epub 2017 Dec 26.

PMID:
29280011
2.

Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.

Kuusalo L, Puolakka K, Kautiainen H, Blåfield H, Eklund KK, Ilva K, Kaipiainen-Seppänen O, Karjalainen A, Korpela M, Valleala H, Leirisalo-Repo M, Rantalaiho V; Neo-RACo Study Group.

Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31.

PMID:
26324784
3.

Towards improved solubility of poorly water-soluble drugs: cryogenic co-grinding of piroxicam with carrier polymers.

Penkina A, Semjonov K, Hakola M, Vuorinen S, Repo T, Yliruusi J, Aruväli J, Kogermann K, Veski P, Heinämäki J.

Drug Dev Ind Pharm. 2016;42(3):378-88. doi: 10.3109/03639045.2015.1054400. Epub 2015 Jun 11.

PMID:
26065533
4.

Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.

Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group.

J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1.

PMID:
25274892
5.

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group.

Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1.

PMID:
23908187
6.

Direct compression of cellulose and lignin isolated by a new catalytic treatment.

Penkina A, Antikainen O, Hakola M, Vuorinen S, Repo T, Yliruusi J, Veski P, Kogermann K, Heinämäki J.

AAPS PharmSciTech. 2013 Sep;14(3):1129-36. doi: 10.1208/s12249-013-0002-x. Epub 2013 Jul 19.

7.

A novel alkaline oxidation pretreatment for spruce, birch and sugar cane bagasse.

Kallioinen A, Hakola M, Riekkola T, Repo T, Leskelä M, von Weymarn N, Siika-aho M.

Bioresour Technol. 2013 Jul;140:414-20. doi: 10.1016/j.biortech.2013.04.098. Epub 2013 May 6.

PMID:
23711947
8.

From hazardous waste to valuable raw material: hydrolysis of CCA-treated wood for the production of chemicals.

Hakola M, Kallioinen A, Leskelä M, Repo T.

ChemSusChem. 2013 May;6(5):813-5. doi: 10.1002/cssc.201200754. Epub 2013 Apr 3.

PMID:
23554264
9.

Solid-state properties of softwood lignin and cellulose isolated by a new acid precipitation method.

Penkina A, Hakola M, Paaver U, Vuorinen S, Kirsimäe K, Kogermann K, Veski P, Yliruusi J, Repo T, Heinämäki J.

Int J Biol Macromol. 2012 Dec;51(5):939-45. doi: 10.1016/j.ijbiomac.2012.07.024. Epub 2012 Jul 27.

PMID:
22846687
10.

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L; ONCE trial group.

Scand J Rheumatol. 2012 Aug;41(4):260-6. doi: 10.3109/03009742.2012.664647.

PMID:
22803768
11.

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group.

Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.

PMID:
22753402
12.

Liberation of cellulose from the lignin cage: A catalytic pretreatment method for the production of cellulosic ethanol.

Hakola M, Kallioinen A, Kemell M, Lahtinen P, Lankinen E, Leskelä M, Repo T, Riekkola T, Siika-aho M, Uusitalo J, Vuorela S, von Weymarn N.

ChemSusChem. 2010 Oct 25;3(10):1142-5. doi: 10.1002/cssc.201000217. No abstract available.

PMID:
20853392
13.

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.

Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, Leirisalo-Repo M, Blåfield H, Puolakka K, Karjalainen A, Möttönen T; FIN-RACo Trial Group.

Arthritis Res Ther. 2010;12(3):R122. doi: 10.1186/ar3060. Epub 2010 Jun 24.

14.

Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.

Karstila KL, Rantalaiho VM, Mustonen JT, Möttönen TT, Hannonen PJ, Leirisalo-Repo M, Kaipiainen-Seppänen OA, Karjalainen AH, Korpela MM; FIN-RACo Trial Group.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1):73-8.

PMID:
20346242
15.

The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.

Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T; FIN-RACo Trial Group.

Arthritis Rheum. 2009 May;60(5):1222-31. doi: 10.1002/art.24447.

16.

Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.

Mäkinen H, Kautiainen H, Hannonen P, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, Blåfield H, Hakola M, Sokka T.

J Rheumatol. 2007 Feb;34(2):316-21. Epub 2006 Dec 15.

PMID:
17183623
17.

Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.

Kuuliala A, Leirisalo-Repo M, Möttönen T, Hannonen P, Nissilä M, Kautiainen H, Korpela M, Julkunen H, Hakola M, Repo H; FIN-RACo Trial Group.

Clin Exp Rheumatol. 2005 Mar-Apr;23(2):243-6.

PMID:
15895898
18.

Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis.

Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Möttönen T, Hakola M, Korpela M, Sanila M, Uksila J, Toivanen A.

Ann Rheum Dis. 2003 Sep;62(9):880-4.

19.

Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.

Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Möttönen T, Hakola M, Korpela M, Sanila M, Parviainen J, Uksila J, Vainionpää R, Toivanen A.

Ann Rheum Dis. 2000 Jul;59(7):565-70.

20.

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Järvinen P, Hakola M, Piirainen H, Ahonen J, Pälvimäki I, Forsberg S, Koota K, Friman C.

Lancet. 1999 May 8;353(9164):1568-73.

PMID:
10334255

Supplemental Content

Loading ...
Support Center